Drug Channels

OCTOBER 21, 2024

Informa Connect’s Trade and Channel Strategies December 10-12, 2024 at the W Hotel in Philadelphia, PA Drug Channels readers save 10% with code 24DC10 * Pharmacy and distribution models are growing increasingly complex. Is my organization haemorrhaging money to stay afloat with the shift to alternative distribution and pharmacy models?

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Marketing Compliance 98

Drug Channels

DECEMBER 10, 2024

This week, Im rerunning some popular posts while I prepare for Fridays Drug Channels Outlook 2025 live video webinar. As you reread the article below, note that some manufacturers have already announced wholesale acquisition cost (WAC) list price declines for 2025. Pharmacies and Pharmacy Benefit Managers.

Pharmacy 52

Pharmacy Pharmaceuticals Drugs Production 52

Fierce BioTech

JANUARY 30, 2025

Self-Serve Hubs: A New Era for HCPs and Medication Access swheeler Thu, 01/30/2025 - 18:54 Thu, 03/27/2025 - 15:00 Resource Type Webinar Dan Cornwell The way healthcare providers (HCPs) navigate medication access is evolving rapidly. On Demand Start Date Thu, 03/27/2025 - 16:00 End Date/Time Thu, 03/27/2025 - 16:00

Pharmacy 52

Pharmacy 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. Manufacturers must sign the agreement by March 1, 2024, to participate in the 2025 plan year. Final Guidance at 2. 1395w-114c(b)(4)(B)(i).

Compliance 105

Compliance Drugs Pharmacy Licensing 105

Drug Channels

SEPTEMBER 10, 2024

I am pleased to announce the full agenda for the inaugural Drug Channels Leadership Forum , which will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. Everyone here at Drug Channels Institute (DCI) is excited to bring this novel event to the drug channels community. I personally assembled the agenda.

Pharmacy 52

Pharmacy Drugs 52

Drug Channels

JUNE 25, 2024

Attendance will be limited, so click here to request an invite for our March 2025 event. Top exceutives from Cencora, Eli Lilly, Optum Rx, and Walgreens will be headlining the inaugural Drug Channels Leadership Forum. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

Biosimilars 40

Biosimilars Drugs Pharmacy 40

Agency IQ

JANUARY 4, 2024

Citizen petitions have raised the alarm regarding benzene in recent years, leading to FDA action Valisure, an analytical pharmacy that first alerted the FDA to concerns associated with nitrosamine impurities , recently set its sights on benzene impurities.

FDA 40

FDA Production Laboratories Drugs 40

Agency IQ

JUNE 16, 2023

The Agenda also includes several long-term actions expected to take place in 2024 and 2025 – included as part of FDA’s long-term regulatory agenda. The rule, will also, if finalized, address communication with State boards of pharmacy. The anticipated date of publication is June 2023, meaning we should see this regulation imminently.

Regulations 40

Regulations FDA Science Production 40

National Institute on Drug Abuse: Nora's Blog

JANUARY 6, 2025

8 Currently in the United States, methadone is only available from specialized opioid treatment centers, but studies piloting access through pharmacies have shown promise. Together, we turn our eye to 2025 and the challenges and opportunities ahead.& Risk of dying was similarly low for both groups.

Treatment 111

Treatment Science Drugs Research 111

Agency IQ

AUGUST 16, 2024

Areas of expertise included psychiatry, post-traumatic stress disorder, emergency medicine, pharmacy and medication safety, and statistics. This study is planned to start in late 2024 and conclude in late 2025. Read AgencyIQ analysis of a recent listening session on the topic here. ].

FDA 40

FDA Trials Therapies Regulations 40

Agency IQ

OCTOBER 27, 2023

WUSF / AgencyIQ November 1 Initial deadline for NDSRIs Under a 2023 guidance document, the FDA has recommended that pharmaceutical companies assess Nitrosamine Drug-Related Substance Impurities for their products by November 1, 2023, with confirmatory testing due by August 1, 2025. What ever happened to that thing?

FDA 40

FDA Science Regulations Production 40

Agency IQ

FEBRUARY 15, 2024

CDER, CBER Draft 12/29/2025 FDA must issue final guidance no later than 18 months after the close of the public comment period for draft guidance. use of RWE, registries) for capturing post-approval safety and efficacy data for cell and gene therapy products.

FDA 40

FDA Science Biosimilars Clinical Trials 40

Drug Channels

NOVEMBER 19, 2024

In Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market , I documented the Inflation Reduction Act’s (IRA) disruption to Medicare Part D prescription drug plans (PDPs). As always, we provide you with a handy table for tallying each chain’s participation and changes from 2024 to 2025. Fein, Ph.D.,

Pharmacy 97

Pharmacy Marketing Drugs 97

Drug Channels

MARCH 11, 2025

Next week, Drug Channels Institute (DCI) will release our 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. For 2024, DCI estimates that total prescription dispensing revenues at retail, mail, long-term care, and specialty pharmacies reached $683 billion, up 9% from the 2023 figure. to 1:30 p.m.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Marketing Drugs 97

Drug Channels

NOVEMBER 13, 2024

For 2025, DCI’s exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that the number of PDPs will drop to a historic low. What’s more, the share of plans with a preferred cost sharing pharmacy network will fall to its lowest rate in more than 10 years. What else should you expect for 2025?

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

JANUARY 22, 2025

For 2025, the three largest pharmacy benefit managers (PBMs)Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)have again each excluded hundreds of drugs from their standard formularies. In fact, nearly all marketed Humira biosimilars are excluded from the larger PBMs 2025 formularies.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Channels

MARCH 31, 2025

Threes still company in the world of pharmacy benefit managers. For a deeper dive into the state of the industry, join me this Friday, April 4, 2025, for our live video webinar: PBM Industry Update: Trends, Challenges, and Whats Ahead. P.S. Special launch pricing on our new 2025 Economic Report on U.S.

Pharmacy 98

Pharmacy Marketing Drugs 98

FDA Law Blog: Biosimilars

FEBRUARY 2, 2025

By Sara M Keup In reviewing some new 2025 pharmacy rules/laws a couple interesting changes caught this bloggers attention: As of December 30, 2024, Missouri has rolled out new rules related to prescription drug delivery requirements. The California Board of Pharmacy updated many of the application forms and guidelines in late 2024.

Licensing 59

Licensing Licensing Pharmacy Packaging 59

Drug Channels

MARCH 18, 2025

I am pleased to announce that Drug Channels Institutes new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is now available for purchase and immediate download. Pharmacies and Pharmacy Benefit Managers. 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Pharmacy 52

Pharmacy Specialty Pharmacies Licensing Licensing 52

Drug Channels

FEBRUARY 18, 2025

Small pharmacies have ghosted Medicare Part Ds preferred networksno farewell party, no breakup text, just a quiet exit. A few months ago , DCI highlighted how the largest pharmacy chains are participating as preferred cost sharing pharmacies in the 2025 stand-alone prescription drug plan (PDP) networks. Abracadabra!

Pharmacy 52

Pharmacy Independent Pharmacies Marketing Drugs 52

Drug Channels

APRIL 1, 2025

Click here to see the original post from January 2025. For 2025, the three largest pharmacy benefit managers (PBMs)Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)have again each excluded hundreds of drugs from their standard formularies. What do you think? All rights reserved.

Biosimilars 52

Biosimilars Pharmacy Production Drugs 52

Drug Channels

FEBRUARY 7, 2025

Todays guest post comes from Richard Faris, Chief Strategy & Growth Officer at PANTHERx Rare Pharmacy. He explains the key considerations for choosing a specialty pharmacy network design, selecting the right pharmacy partners, and establishing patient services HUBs. Read on for Richards insights. All rights reserved.

Specialty Pharmacies 64

Specialty Pharmacies Pharmacy Disease Treatment 64

Drug Channels

FEBRUARY 25, 2025

In this issue: How Part D plan sponsors responded to pharmacy DIR changes Troubling new data on copay accumulators in marketplace plans DCIs latest vertical integration visualization How the IRA will hurt physician practices Plus, cartoon cats explain the 340B Drug Pricing Program. Winteror at least Februaryis almost over.

Pharmacy 59

Pharmacy Drugs 59

Drug Channels

MARCH 21, 2025

Greg discusses some of the challenges manufacturers face with product commercialization, patient access and adherence, and negotiating partnerships with pharmacy benefit managers (PBMs). Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Read on for Greg's insights.

Pharmacy 98

Pharmacy Production Drugs 98

FDA Law Blog: Biosimilars

FEBRUARY 18, 2025

Hull A recent DEA decision revoking the registration of a Louisiana pharmacy sheds light on the Agencys approach to crediting one experts testimony over that of another expert during an administrative hearing. In Neumanns Pharmacy, LLC , 90 Fed. By Andrew J.

Testimonials 69

Testimonials Pharmacy Government Drugs 69

Drug Channels

JANUARY 14, 2025

During my recent Drug Channels Outlook 2025 video webinar, I tackled a wide range of crucial topicsincluding the controversial 340B Drug Pricing Program. As I explain in this video excerpt, we may finally see reform of this rapidly expanding program.

Pharmacy 52

Pharmacy Hospitals Marketing Drugs 52

Drug Channels

DECEMBER 11, 2024

This week, Im rerunning some popular posts while I prepare for Fridays Drug Channels Outlook 2025 live video webinar. In the video excerpt below, I walk through a brief history of 340B contract pharmacies. I conclude with a follow the dollar example of 340B prescription economics with contract pharmacies.

Pharmacy 52

Pharmacy Hospitals Marketing Drugs 52

Drug Channels

MARCH 26, 2025

on April 4, 2025, from 12:00 p.m. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. P.S. Join my more than 61,000 LinkedIn followers for daily links to neat stuff along with thoughtful and provocative commentary from the DCI community. Join Adam J. Fein, Ph.D., to 1:30 p.m.

Biosimilars 52

Biosimilars Pharmacy Drugs 52

Drug Channels

JANUARY 28, 2025

healthcare system Trick Play : Patients and plans get sacked by a gross spending-to-net bubble Defensive line : A comeback for pharmacy students Offensive line : Apexus dances in the end zone, while a 340B hospital tackles a patient Plus, Super Antonio runs downfield in the Mushroom Kingdom. ( No, that's not a typo. All rights reserved.

Pharmacy 59

Pharmacy Hospitals Drugs 59

Drug Channels

JANUARY 7, 2025

Employers, health plans, and pharmacy benefit managers (PBMs) determine the extent to which patients with insurance share in this ongoing deflation. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. But signs of change to the conventional approaches are undeniable. All rights reserved.

Pharmacy 90

Pharmacy Drugs Production 90

Drug Channels

APRIL 4, 2025

Click here to see the original post from January 2025. Employers, health plans, and pharmacy benefit managers (PBMs) determine the extent to which patients with insurance share in this ongoing deflation. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. brand-name drug pricing.

Pharmacy 52

Pharmacy Drugs Production 52

Drug Channels

DECEMBER 17, 2024

This landmark event will take place in March 2025 in Miami. (If Wishing you and your family health and happiness, Adam and the DCI team In this issue: Unexplainable pharmacy reimbursements in Medicare Part D Surprise! Did you miss the Drug Channels Outlook 2025 video webinar? In January, HMP Global acquired DCI. No worries!

Pharmacy 40

Pharmacy Independent Pharmacies Drugs 40

Fierce BioTech

JANUARY 31, 2025

10 Patient Engagement Strategies to Boost Medication Adherence pesurya Fri, 01/31/2025 - 10:23 Mon, 03/24/2025 - 11:00 Resource Type Webinar Josh Weiner Krystle Thornton Promotion Start Fri, 01/31/2025 - 12:30 Promotion End Mon, 07/28/2025 - 12:30 Studies show 50% of patients dont take their medication as prescribed.

Pharmacy 52

Pharmacy Therapies 52

Drug Channels

APRIL 2, 2025

Below, I do a wicked deep dive into the data and highlight crucial implications about spending, profits, pharmacies, plans, patients, program integrity, and more. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. There are important limitations to these data.

Pharmacy 52

Pharmacy Drugs Hospitals 52

Fierce BioTech

MARCH 28, 2025

From catch-all to calibrated: A more targeted approach to pharma DTC marketing Explore how pharma marketers can optimize impact by leveraging pharmacy retail media to reach high-intent audiences. dfarris Fri, 03/28/2025 - 08:30 Explore how pharma marketers can optimize impact by leveraging pharmacy retail media to reach high-intent audiences.

Marketing 40

Marketing Pharmacy 40

Drug Channels

DECEMBER 3, 2024

Below, I do a wicked deep dive into the data and highlight crucial implications about spending, profits, pharmacies, plans, patients, program integrity, and more. During next week’s Drug Channels Outlook 2025 live video webinar, he'll tell you what's ahead for the program that continues to defy gravity.

Pharmacy 52

Pharmacy Doctors Drugs Hospitals 52

FDA Law Blog: Biosimilars

NOVEMBER 11, 2024

Comments on the proposed order are due May 25, 2025. Whether those products will be reformulated to include pseudoephedrine and then held behind-the-counter is unknown but seems unlikely as well as unwelcome from the standpoint of pharmacy management. That means almost certainly no sooner than the second half of 2026.

FDA 111

FDA Production Pharmacy International 111